Studied group

Regimen of treatment

Total No.

SVR 12

Relapsers plus patients stopped treatment

Group 1

SOF/DAC

95

91 (95,8%)

4 (4,2%)

Group 2

SOF/DAC+RIB

32

30 (93,8%)

2 (6,2%)